Skip to main content

Flavoxate Pregnancy and Breastfeeding Warnings

Brand names: Urispas

Medically reviewed by Drugs.com. Last updated on Aug 11, 2023.

Flavoxate Pregnancy Warnings

Use is recommended only if clearly needed.

US FDA pregnancy category: B

Animal studies have failed to reveal evidence of impaired fertility and fetal harm. There are no controlled data in human pregnancy.

US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

See references

Flavoxate Breastfeeding Warnings

Caution is recommended.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: During long-term use, observe the breastfeeding infant for signs of decreased lactation (e.g., insatiety, poor weight gain).

See references

Does Flavoxate interact with my other drugs?

Enter medications to view a detailed interaction report using our Drug Interaction Checker.

References for pregnancy information

  1. MHRA. Medicines and Health Regulatory Agency (2013) MHRA Drug Safety Update. http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate
  2. (2022) "Product Information. FlavoxATE Hydrochloride (flavoxATE)." PuraCap Pharmaceutical

References for breastfeeding information

  1. United States National Library of Medicine (2013) Toxnet. Toxicology Data Network. http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT
  2. MHRA. Medicines and Health Regulatory Agency (2013) MHRA Drug Safety Update. http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate
  3. (2022) "Product Information. FlavoxATE Hydrochloride (flavoxATE)." PuraCap Pharmaceutical

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.